110 related articles for article (PubMed ID: 34610216)
1. Possibility of paclitaxel to induce the stemness-related characteristics of prostate cancer cells.
Içduygu FM; Samli H; Özgöz A; Vatansever B; Oztürk KH; Akgün E
Adv Clin Exp Med; 2021 Dec; 30(12):1283-1291. PubMed ID: 34610216
[TBL] [Abstract][Full Text] [Related]
2. CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel.
Aghajani M; Mokhtarzadeh A; Aghebati-Maleki L; Mansoori B; Mohammadi A; Safaei S; Asadzadeh Z; Hajiasgharzadeh K; Khaze Shahgoli V; Baradaran B
Mol Biol Rep; 2020 May; 47(5):3691-3703. PubMed ID: 32246247
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
4. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
[TBL] [Abstract][Full Text] [Related]
5. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
[TBL] [Abstract][Full Text] [Related]
6. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
7. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
[TBL] [Abstract][Full Text] [Related]
8. MiR-145 inhibits cell migration and increases paclitaxel chemosensitivity in prostate cancer cells.
Tohidast M; Memari N; Amini M; Hosseini SS; Jebelli A; Doustvandi MA; Baradaran B; Mokhtarzadeh A
Iran J Basic Med Sci; 2023; 26(11):1350-1359. PubMed ID: 37886001
[TBL] [Abstract][Full Text] [Related]
9. CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
Li Y; Mizokami A; Izumi K; Narimoto K; Shima T; Zhang J; Dai J; Keller ET; Namiki M
Prostate; 2010 Jan; 70(1):48-60. PubMed ID: 19725034
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PER3 reverses paclitaxel resistance of prostate cancer cells by inhibiting the Notch pathway.
Cai DW; Chen D; Sun SP; Liu ZJ; Liu F; Xian SZ; Wu PS; Kong GQ
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2572-2579. PubMed ID: 29771413
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for paclitaxel resistance in human epithelial type 2 cells.
Duz MB; Karatas OF
Mol Biol Rep; 2021 Feb; 48(2):1393-1400. PubMed ID: 33506275
[TBL] [Abstract][Full Text] [Related]
12. Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells.
Park SY; Kim MJ; Park SA; Kim JS; Min KN; Kim DK; Lim W; Nam JS; Sheen YY
Oncotarget; 2015 Nov; 6(35):37526-43. PubMed ID: 26462028
[TBL] [Abstract][Full Text] [Related]
13. Characterization of OCT3/4, Nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer.
Costa CD; Justo AA; Kobayashi PE; Story MM; Palmieri C; Laufer Amorim R; Fonseca-Alves CE
Int J Biochem Cell Biol; 2019 Mar; 108():21-28. PubMed ID: 30633985
[TBL] [Abstract][Full Text] [Related]
14. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
Xue YN; Yu BB; Liu YN; Guo R; Li JL; Zhang LC; Su J; Sun LK; Li Y
Prostate; 2019 May; 79(6):647-656. PubMed ID: 30714183
[TBL] [Abstract][Full Text] [Related]
15. Possible roles of vinexinbeta in growth and paclitaxel sensitivity in human prostate cancer PC-3 cells.
Mizutani K; Nagata K; Ito H; Ehara H; Nozawa Y; Deguchi T
Cancer Biol Ther; 2007 Nov; 6(11):1800-4. PubMed ID: 18032926
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
Samli H; Samli M; Vatansever B; Ardicli S; Aztopal N; Dincel D; Sahin A; Balci F
World J Urol; 2019 Jun; 37(6):1117-1126. PubMed ID: 30244336
[TBL] [Abstract][Full Text] [Related]
17. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties.
Ma Y; Liang D; Liu J; Axcrona K; Kvalheim G; Stokke T; Nesland JM; Suo Z
PLoS One; 2011; 6(12):e29170. PubMed ID: 22216200
[TBL] [Abstract][Full Text] [Related]
19. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Miyake H; Chi KN; Gleave ME
Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
[TBL] [Abstract][Full Text] [Related]
20. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma.
Tsai LL; Yu CC; Chang YC; Yu CH; Chou MY
J Oral Pathol Med; 2011 Sep; 40(8):621-8. PubMed ID: 21342274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]